1. Introduction {#s0005}
===============

Mitochondrial diseases are a heterogeneous group of genetic disorders resulting in significant morbidity and disability, and affecting up to 8000 adults in the UK [@bb0005]. The m.3243A\>G mutation in the mt-tRNALeu^(UUR)^ *MTTL1* gene is the most common pathogenic mutation, present in \~ 1 in 300 of the general population and causing disease in \~ 1 in 6000 individuals [@bb0010]. The clinical phenotype is highly variable: originally described in patients with mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS), the m.3243A\>G mutation can also cause maternally inherited diabetes and deafness (MIDD), myopathy, ophthalmoplegia and cardiomyopathy, as isolated clinical features or part of multisystem disease [@bb0365]. Despite this phenotypic variability, exercise intolerance and fatigue are common clinical symptoms.

There are currently limited therapeutic options for patients with mitochondrial disease [@bb0020]. Endurance exercise training has, however, been demonstrated to improve exercise tolerance, quality of life and skeletal muscle oxidative capacity in this patient group, reversing baseline de-conditioning [@bb0025; @bb0030; @bb0035; @bb0040]. Resistance exercise training has been linked to similar clinical improvements in patients with mitochondrial disease [@bb0045]. While the cellular mechanisms underlying the effects of exercise training are yet to be fully elucidated, no deleterious clinical outcomes related to skeletal muscle function, quality of life or disease progression have been reported in studies from diverse genotypic groups. Yet clinical equipoise exists with regard to cardiac parameters, and understandable concerns of adverse remodelling, in a cohort of patients prone to cardiac abnormalities, may have restricted the widespread uptake of therapeutic endurance exercise training in patients with mitochondrial disease, hampering clinical care. Cardiomyopathy, most commonly with a hypertrophic phenotype, occurs in 20--40% of patients carrying the m.3243A\>G mutation [@bb0050; @bb0055; @bb0060; @bb0065; @bb0070], and is an independent predictor of morbidity and early mortality [@bb0065; @bb0075]. Impaired cardiac bioenergetics also occur in patients with m.3243A\>G-related mitochondrial disease [@bb0080; @bb0370], and are predictive of prognosis in diverse forms of cardiomyopathy [@bb0375]. Cardiovascular autonomic dysfunction has been demonstrated in patients harbouring the m.3243A\>G mutation [@bb0095; @bb0100], and is independently associated with an increased risk of sudden death in the general population, after myocardial infarction [@bb0105].

In untrained individuals without mitochondrial disease, endurance exercise training increases left ventricular mass, ventricular cavity dimensions and haemodynamic parameters of cardiac function [@bb0110; @bb0115; @bb0120]. Similarly, exercise in patients with established heart failure reduces symptoms and improves cardiac function, exercise tolerance, quality of life and daily activity levels, *without* a significant deleterious effect on impaired cardiac bioenergetics [@bb0125; @bb0130; @bb0135]. However whether similar effects occur in patients with mitochondrial disease is unknown. Magnetic resonance imaging (MRI) is the gold standard investigation of cardiac morphology and, combined with cardiac tagging and phosphorus-31 (^31^P) magnetic resonance spectroscopy (MRS) enables detection of subclinical defects in both myocardial deformation and bioenergetics. Using these modalities, we sought to characterize the effects of endurance exercise training on disease burden, resting cardiac function, high energy phosphate metabolism, cardiovascular autonomic function, fatigue and quality of life in a clinically and genetically well-characterized cohort of patients with m.3243A\>G-related mitochondrial disease with reference to age- and gender- and habitual physical activity level-matched controls.

2. Methods {#s0010}
==========

2.1. Participants {#s0030}
-----------------

Ten patients with mitochondrial disease due to the m.3243A\>G mutation, but without known cardiac involvement, were recruited from consecutive attendees at a specialist outpatient clinic between August 2010 and July 2011. All eligible patients were verbally invited to participate in the study based on the following clinical inclusion criteria: (i) clinical stability for \> 6 months; (ii) ability to use a semi-recumbent stationary bicycle ergometer; and (iii) no current participation in regular physical activity (≥ 1 weekly session). Exclusion criteria were the presence of known cardiac involvement (determined using clinical history, examination, 12-lead ECG and echocardiogram), comorbidities precluding exercise training (e.g. osteoarthritis), and contra-indications to MRI, including the presence of a pacemaker or implantable cardioverter-defibrillator, abnormal renal function (eGFR \< 60 ml/min/1.73 m^2^) or claustrophobia. All 10 patients were matched with respect to age, gender and physical activity level with untrained healthy controls with normal ECG and no history of cardiovascular or metabolic disease, recruited through local advertisement. Institutional ethical approval and written informed consent were obtained.

2.2. Assessments {#s0035}
----------------

All baseline and follow-up assessments were completed on a single day. Assessments of exercise parameters, autonomic function, resting venous lactate and creatine kinase (CK) were performed between 0800 and 1000 following an overnight fast (\> 10 h), and cardiac MRI took place at the same time of day throughout the study for each subject. All subjects were asked to refrain from smoking, alcohol ingestion, physical exertion and medications that could influence haemodynamic, exercise or autonomic parameters (including β blockers, calcium channel blockers, anti-depressants) for 24 h prior to assessment.

2.3. Exercise testing {#s0040}
---------------------

Cardiopulmonary exercise testing was performed using analysis of expired air gases (Metalyzer 3B; Cortex, Leipzig, Germany) and non-invasive bioreactance cardiac output (NICOM; Cheetah Medical, Maidenhead, UK) on a calibrated, electronically braked stationary bicycle ergometer (Corival®; Lode, Groningen, Netherlands) at a steady cadence between 60 and 80 bpm. During all visits, a stepped incremental workload test (\~ 10--20 W/min) was conducted to elicit a symptom-limited maximum oxygen uptake and heart rate response. Respiratory gas exchange data were collected continuously and the Borg Rating of Perceived Exertion (RPE) score performed every 3 min. Exercise was terminated when subjects developed severe dyspnoea or peripheral muscle fatigue and were physically exhausted (as indicated by respiratory exchange ratio (RER) \> 1.1, Borg RPE score \> 18 or absence of rise in oxygen consumption with further increases in exercise intensity). Anaerobic threshold was determined using the V-slope method, as previously described [@bb0145]. Baseline physical activity was assessed using an armband accelerometer SenseWear® Armband multi-array physical activity monitor (Bodymedia, Pittsburgh, USA) worn for seven days.

Cardiac power output (in Watts) was calculated as the product of mean arterial pressure (in mm Hg), cardiac output (in litres/min) and the conversion factor 2.22 × 10^− 3^ [@bb0150]. Arterial--venous oxygen difference, expressed in ml O~2~/100 ml of blood, was calculated as the ratio of peak oxygen consumption and cardiac output.

2.4. Disease burden {#s0045}
-------------------

Subjects underwent physical examination by experienced clinicians (GSG and MGDB). Disease burden in patients was assessed using the Newcastle Mitochondrial Disease Adult Scale (NMDAS), a validated rating system [@bb0155], whilst mutation load was determined in urinary epithelial cells, an established marker of clinical status in patients with the m.3243A\>G mutation [@bb0160].

2.5. Body weight and composition {#s0050}
--------------------------------

Subject heights were recorded for body mass index and body surface area calculations. Body weights, body fat percentages and lean body weights were measured using air displacement plethysmography (BODPOD®; COSMED, Rome, Italy).

2.6. Cardiac magnetic resonance imaging {#s0055}
---------------------------------------

Using a 3-Tesla scanner, cardiac MRI was performed to include: (i) ^31^P MRS (ii) cine imaging, and (iii) cardiac tagging, as previously described and validated in this patient cohort [@bb0370; @bb0165].

### 2.6.1. Cardiac ^31^P MRS {#s0060}

Subjects were scanned prone with a ^31^P surface coil using a cardiac-gated, 1-dimensional chemical shift imaging sequence. Sixteen coronal phase-encoding steps (TR = heart rate, 192 averages) yielded spectra from 10 mm slices. The first spectrum arising entirely beyond the chest wall was analysed using AMARES time domain fit [@bb0170] to quantify phosphocreatine (PCr), the γ resonance of adenosine triphosphate (ATP), corrected for blood contamination, and their ratio (PCr/ATP), as a marker of cardiac bioenergetics [@bb0370].

### 2.6.2. Cardiac cine imaging {#s0065}

Subjects were scanned supine with steady-state free precession images, using a 6-channel cardiac coil and ECG gating \[field of view (FOV) 350 × 350 mm^2^, repetition time/echo time (TR/TE) = 3.7/1.9 ms, turbo factor 17, flip angle (FA) 40°, slice thickness 8 mm, 25 phases, resolution 1.37 mm\]. Left ventricular (LV) mass and systolic and diastolic parameters were calculated as previously described [@bb0370; @bb0165].

### 2.6.3. Cardiac tagging {#s0070}

MR signal from myocardium in diastole was cancelled in a rectangular grid pattern and tags were tracked through the cardiac cycle ([Fig. 1](#f0005){ref-type="fig"}A) [@bb0175]. A multi-shot turbo-field echo sequence was used (TR/TE/FA/number of averages = 4.9/3.1/10°/1, turbo factor 9, SENSE factor 2, FOV 350 × 350 mm^2^, voxel size 1.37 mm, tag spacing 7 mm, 12 phases). Peak circumferential strain for both the whole myocardial wall and the endocardial third were calculated. Peak torsion between two adjacent short-axis slices was calculated as the circumferential-longitudinal shear angle, defined on the epicardial surface ([Fig. 1](#f0005){ref-type="fig"}B).

2.7. Autonomic function {#s0075}
-----------------------

### 2.7.1. Apparatus {#s0080}

All participants underwent assessment of autonomic function over 30 min at rest in a cardiorespiratory laboratory using the Task Force Monitor (TFM; CNSystems, Graz, Austria), which provides automated and computed beat-to-beat analysis of heart rate and blood pressure. Biological inputs to the system are provided by: (i) 3-lead ECG; (ii) impedance cardiography; and (iii) continuous, non-invasive blood pressure, recorded using finger plethysmography with intermittently calibration to contralateral oscillometric blood pressure measurements. From these data, the TFM calculates continuous, reliable measurements of haemodynamic and autonomic parameters [@bb0180; @bb0185; @bb0190].

### 2.7.2. Heart rate variability (HRV) and blood pressure variability (BPV) {#s0085}

Power spectral analysis for HRV and BPV was conducted using an adaptive auto-regressive (AAR) model as previously described [@bb0195]. In addition to total power spectral density (PSD), the low frequency (LF, 0.05--0.17 Hz) and high frequency (HF, 0.17--0.4 Hz) components of the signal were automatically calculated using the TFM. All components are reported in normalized units (nu) for RR interval (RRI), systolic blood pressure (SBP) and diastolic blood pressure (DBP) parameters (LFnu-RRI, HFnu-RRI, LFnu-SBP, HFnu-SBP, LFnu-DBP, and HFnu-DBP). As previously described, all LF components refer to sympathetic modulation of the sinus node activity and vasomotor function, while HF components refer to parasympathetic modulation of such cardiovascular activity. The ratios of LF and HF components provide a marker of sympatho-vagal balance (LF:HF-RRI, LF:HF-SBP, and LF:HF-DBP) [@bb0200; @bb0205].

2.8. Fatigue and quality of life {#s0090}
--------------------------------

Standard, validated self-completion questionnaires were used for the assessment of fatigue (Fatigue Impact Scale (FIS)) and quality of life (the Short-Form 12 (SF-12)).

2.9. Exercise intervention {#s0095}
--------------------------

Participants were instructed to perform 30 min of cycling (excluding 5 min of warming-up and cooling-down) on an upright ergometer, three times per week, for 16 weeks at a self-regulated workload that achieved a heart rate corresponding to 70--80% of the symptom-limited maximum oxygen uptake, and a Borg RPE score 12--14. Target heart rate for all subjects was monitored using an RS100 watch (Polar Electro, Finland) and adjusted at 8 weeks following completion of a maximal graded cardiopulmonary exercise test. Workload was adjusted continuously during all training sessions to achieve target heart rates. Participants were asked to limit training to the prescribed programme, and, although exercise training was unsupervised, all subjects received weekly phone calls to ensure compliance with exercise training, and completed exercise diaries that were regularly reviewed by study investigators.

2.10. Statistical analysis {#s0100}
--------------------------

Data are presented as means ± SD for continuous data and as numbers or percentages for categorical data. Continuous data were tested for normality, linearity and homogeneity of covariance matrices. A mixed model multivariate analysis of variance was performed between patients and controls, before and after completion of the exercise intervention. Group (patient or control) and time (baseline or follow-up) were respected as factors and physiological parameters were taken as the dependent variables. The interaction between group and time conditions permitted detection of any differences in the response to exercise. Where the mixed model main factors or interaction were statistically significant, subsequent between group comparisons were made using unpaired Student\'s *t*-tests or Mann--Whitney U tests and within group comparisons using paired Student\'s *t*-tests or Wilcoxon signed rank tests. Categorical variables were compared using Fisher\'s exact test and correlations were executed using Pearson\'s method. All analysis was performed using SPSS version 17 (SPSS Inc., Chicago, Illinois). All tests were two-sided and statistical significance was assumed at *p* \< 0.05.

3. Results {#s0015}
==========

3.1. Patient group characteristics {#s0105}
----------------------------------

The baseline characteristics of 10 patients (9 probands) and 10 control subjects, matched for age, gender and habitual physical activity, are presented in [Table 1](#t0005){ref-type="table"}. Body mass index (BMI) and body surface area (BSA) were significantly lower in patients than controls. Cardiovascular disease features and relevant medications are included in [Table 1](#t0005){ref-type="table"}: five patients had diabetes mellitus and one had treated hypertension. There were no significant differences in current systolic or diastolic blood pressures.

Patient details including specific clinical features, mutation loads and baseline NMDAS, FIS and SF-12 scores are presented in [Table 2](#t0010){ref-type="table"}. Disease burden was mild or moderate in all patients with phenotypes consistent with MIDD (five patients), myopathy (three patients), MELAS (one patient) and oligosymptomatic status (one patient). The frequencies of specific clinical features in this group are presented in Supplementary Table 1. Fatigue was a clinical feature of mitochondrial disease in five patients (50%): three patients reported excessive fatigue (FIS score ≥ 40) and one patient reported severe fatigue (FIS score ≥ 80).

3.2. Exercise training {#s0110}
----------------------

All patients and control subjects completed ≥ 80% of the 48 scheduled training sessions, and no adverse events were reported. All patients remained clinically stable throughout the study, and there were no changes in medication.

Cardio-pulmonary exercise testing responses for patients and controls before and after completion of the exercise training programme are presented in [Table 3](#t0015){ref-type="table"}. There was no significant effect of subject status (patient or control) on the response to endurance exercise in any haemodynamic, exercise physiology or cardiac parameter.

3.3. Haemodynamic parameters {#s0115}
----------------------------

At peak exercise stroke volume, heart rate, cardiac output, and cardiac index, were all decreased in patients compared to controls ([Table 3](#t0015){ref-type="table"}), achieving statistical significance at either baseline or follow-up or both time-points for each of these parameters. There were no significant differences between the groups in peak systolic, diastolic or mean arterial blood pressures or in cardiac power output, when indexed to BSA (CPO index). Although there was a trend towards reduction in peak heart rate following exercise training in both groups, this only achieved statistical significance in controls (mean decrease 7 bpm, *p* = 0.001).

3.4. Exercise physiology {#s0120}
------------------------

At baseline, peak VO~2~, peak arterial--venous oxygen difference (A--VO~2~ diff), and peak power were all significantly decreased in patients compared to controls (mean decreases 22%, 30%, 23% and 77% respectively). The anaerobic threshold (AT) at baseline, when expressed as a percentage of predicted peak VO~2~, was significantly decreased in patients compared to controls, while absolute values showed a supportive trend in the same direction. In both patient and control groups, sixteen weeks of endurance exercise training significantly increased peak work capacity (power, 12% and 13% respectively), peak oxygen uptake (VO~2~, 16% and 10%), and anaerobic threshold (AT, 23% and 23%) without a significant change in CPO or CPOI. In patients, there was a non-significant trend towards an increase in peak capacity for oxygen extraction (A--VO~2~ diff, 12%, *p* = 0.059). Resting venous lactate and creatine kinase were not significantly different at baseline between patients and controls and there was no significant effect of endurance exercise training on these blood parameters, in either group (Supplementary Table 2).

3.5. Body composition {#s0125}
---------------------

Although significant between-group differences existed at baseline, there were no significant changes in body weight or BMI in patient or control groups in response to exercise training (Supplementary Table 2). In patients, there was a non-significant trend towards an increase in lean body weight (mean increase 1.0 kg, *p* = 0.056) following the endurance exercise training intervention.

3.6. Cardiac structure and function {#s0130}
-----------------------------------

[Table 4](#t0020){ref-type="table"} summarizes the cardiac MRI structural and functional parameters for patient and control groups. The means and ranges of control group parameters are in agreement with a large cohort study using quantitative cardiac MRI [@bb0210].

At baseline, end-systolic and end-diastolic cardiac volumes were proportionally decreased in patients compared to controls, with no difference in ejection fraction ([Table 4](#t0020){ref-type="table"}). Stroke volume was also decreased in patients: this occurred in association with an increase in heart rate (r = − 0.71, *p* = 0.021), with no difference in cardiac output. Endurance exercise had no significant effect on cardiac volumes or global systolic or diastolic function in patients or controls.

LV mass index (LVMI) was significantly increased in patients compared to controls ([Table 4](#t0020){ref-type="table"}) at baseline, but remained within the normal range, as LVMI did not fulfil the definition of left ventricular hypertrophy (LVH) in any patient. A significant increase in M/V ratio (57%, *p* = 0.001) suggested that this subclinical difference represented concentric remodelling. Cardiac mass increased significantly in both patient and control groups following endurance exercise, with similar proportional sizes of effect: LVM (mean increases 13% and 16% respectively, [Fig. 2](#f0010){ref-type="fig"}), LVMI (13% and 17%), and M/V ratio (5% and 10%). Subject status (patient or control) had no significant effect on the effect of exercise on LVMI ([Fig. 3](#f0015){ref-type="fig"}A).

3.7. Cardiac tagging and myocardial strains {#s0135}
-------------------------------------------

At baseline, there was evidence of altered myocardial strains in patients consistent with subclinical concentric remodelling ([Table 4](#t0020){ref-type="table"}): longitudinal shortening was significantly decreased (18%) and correlated significantly with increased LVMI (r = − 0.61, *p* = 0.03). Peak torsion was increased (54%) and endocardial circumferential strain was decreased (17%) in patients compared to controls, with a subsequent significant increase in their ratio, the TSR (95%). There were, however, no significant effects of exercise on myocardial strains or torsion in either patients or controls.

3.8. Myocardial bioenergetics {#s0140}
-----------------------------

At baseline, PCr/ATP ratio was decreased in patients compared to controls (mean decrease 26%, *p* = 0.002, [Table 4](#t0020){ref-type="table"}). Seven patients (70%) but no controls had an abnormal PCr/ATP ratio (\< 1.6) [@bb0375], but there was no significant difference in markers of disease burden, cardiac structure or function between patients with PCr/ATP ratio \> 1.6 and those \< 1.6.

There was no significant effect of exercise training on the PCr/ATP ratio in patients or controls ([Fig. 3](#f0015){ref-type="fig"}B), and no significant difference in the response to exercise between the groups ([Table 4](#t0020){ref-type="table"}). There was a trend towards an increase in the PCr/ATP ratio in patients following exercise training (mean increase 11%, *p* = 0.260). PCr/ATP ratio increased in six patients and decreased in four patients after exercise training --- at follow-up only four patients (40%) had a ratio \< 1.6 ([Fig. 3](#f0015){ref-type="fig"}B). Representative ^31^P MR spectra are shown ([Fig. 4](#f0020){ref-type="fig"}).

3.9. Quality of life and disease burden {#s0145}
---------------------------------------

At baseline, patients had NMDAS scores averaging 16 ± 7, which correlated with FIS score (r = 0.784, *p* = 0.007), but not urinary m.3243A\>G mutation load (r = 0.465, *p* = 0.176) or SF-12 scores (r = 0.234, *p* = 0.477). After exercise training there was no significant change in NMDAS or SF-12 quality-of-life scores in patients (Supplementary Table 3).

3.10. Fatigue and autonomic function {#s0150}
------------------------------------

FIS scores, both at baseline and after exercise training, were significantly increased in patients compared to controls ([Table 5](#t0025){ref-type="table"}), but there was no significant effect of exercise on FIS score in either group; the proportion of patients reporting excessive or severe fatigue at baseline (40%) was unchanged following exercise training.

Consistent with the significant elevation in resting heart rate, mean RR interval was significantly decreased in patients compared to controls ([Table 5](#t0025){ref-type="table"}). LF:HF-RRI was significantly increased (mean increase 79%, *p* = 0.03) in patients compared to controls, providing evidence of a shift in sympatho-vagal balance, with effects predominantly driven through an increase in sympathetic function (LFnu-RRI). Total diastolic BPV (PSD-DBP) was significant decreased in patients compared to controls both before and after exercise training ([Table 5](#t0025){ref-type="table"}). A significant shift in sympatho-vagal balance was again evident in patients compared to controls (LF:HF-DPB), but driven here by a decrease in high frequency components, representing parasympathetic function (HFnu-DBP). There was no significant effect of exercise training on any HRV or BPV parameter in either group.

4. Discussion {#s0020}
=============

The principal findings of this study of the effects of a 16-week endurance exercise training programme in patients harbouring the m.3243A\>G mutation compared to controls are: 1) endurance exercise is safe with no deleterious effects on cardiac morphology and function; 2) patients achieved similar proportional benefits of training on cardio-pulmonary and haemodynamic parameters including peak work capacity, peak oxygen uptake and anaerobic threshold, with no evidence of disease progression or increased fatigue compared to sedentary controls; 3) reduced exercise capacity detected at baseline, is predominately mediated through peripheral skeletal muscle dysfunction, rather than central cardiac factors; and 4) increased sympathetic and decreased parasympathetic cardiovascular autonomic activity pre- and post-exercise training suggests a role for sympathetic over-activation in disease pathogenesis.

4.1. Reduced exercise capacity and skeletal muscle function {#s0155}
-----------------------------------------------------------

Consistent with a previous case--control study of patients with mitochondrial disease [@bb0040], peak oxygen consumption, peak arterial--venous oxygen difference and peak work capacity at baseline were significantly decreased in patients compared to untrained, sedentary controls, with proportional reductions in peak exercise haemodynamic parameters. Despite these facts, all patients completed the 16-week endurance exercise training intervention (≥ 80% of the 48 scheduled sessions) and no adverse events were reported. Participants remained medically stable throughout the study with no deleterious changes in markers of disease burden, skeletal muscle dysfunction or quality of life.

Limitations in exercise parameters at baseline in patients were not reflected in indexed peak cardiac power output, which was not statistically different to controls. This suggests that the reduction in maximal exercise capacity and the associated symptom of exercise intolerance in patients with the m.3243A\>G mutation is related to reduced peripheral ability of the skeletal muscle to extract oxygen during exercise, rather than to a central cardiac limitation. This potential mechanism is consistent with previous studies that have reported preservation, or even elevation, of skeletal muscle oxygen delivery [@bb0215; @bb0220; @bb0225; @bb0230; @bb0235; @bb0240; @bb0245; @bb0250; @bb0255; @bb0260; @bb0265], endothelial function, and oxygen unloading mechanisms [@bb0215] in similar cohorts of patients with mitochondrial disease. To our knowledge, this is the first study to definitively exclude central cardiac factors as a mediator of reduced exercise capacity in this cohort of patients. Moreover, a similar blunted response to exercise resulting from limited peripheral muscle oxygen extraction has been reported in other disease states, where skeletal muscle dysfunction, and indeed peripheral mitochondrial abnormalities, have been implicated in the aetiology of reduced exercise capacity, including stroke [@bb0270], heart failure [@bb0275; @bb0280; @bb0380], chronic obstructive pulmonary disease (COPD) and chronic renal failure [@bb0290]. Interestingly, while the anaerobic threshold of patients in our study was reduced compared to controls when expressed relative to *predicted* peak oxygen consumption, there was no significant difference in the absolute values or those relative to the *actual* peak oxygen consumption between the groups. This implies that skeletal muscle oxidative consumption may be similar between the groups, suggesting that peripheral factors other than mitochondrial oxidative metabolism may contribute to reduced, exercise tolerance seen in patients with mitochondrial disease. Biopsy studies have previously demonstrated an increase in skeletal muscle oxidative capacity and respiratory chain enzymatic complex activities with exercise training in patients with mitochondrial disease [@bb0040; @bb0045], but further interventional studies would be necessary to examine other skeletal muscle factors in this patient group.

Endurance exercise training improved peak work capacity, peak oxygen consumption and anaerobic threshold in both patient and control groups. This expected result is similar to previous aerobic exercise training studies in patients with mitochondrial disease [@bb0030; @bb0045], and occurred without an improvement in CPO or indexed CPO. This further suggests that training improvements in exercise capacity, as well as the baseline restrictions in these parameters, are manifestations of skeletal muscle rather than cardiac involvement in mitochondrial disease. The trend towards an improvement in peak arterio--venous oxygen difference at peak exercise in patients following a 16-week aerobic exercise training intervention suggests an increased ability of the skeletal muscle to extract and utilise oxygen during aerobic exercise as a result of the training programme. The ability of skeletal muscle to extract oxygen during exercise represents an important and physiologically-relevant surrogate marker of skeletal muscle mitochondrial function, and our data suggest that although this parameter is blunted in patients with mitochondrial disease due to the m.3243A\>G mutation, it can be improved by exercise training and that the magnitude of this improvement is similar to that in untrained, sedentary controls. Similarly, despite a much lower weight at baseline, patients showed a trend towards an increase in lean body mass following exercise training, which may represent morphological changes in skeletal muscle. Importantly, although all patients in this study reported the clinical feature of exercise intolerance, and fatigue was noted in half, there was no deleterious effect of exercise training on fatigue or reported quality of life. This finding occurred despite an *increase* in exercise capacity in patients, suggesting a clinical benefit in this group.

4.2. Endurance exercise and cardiac remodelling {#s0160}
-----------------------------------------------

Our group has previously demonstrated, in similar cohorts, that patients harbouring the m.3243A\>G mutation, without known cardiac involvement on standard screening, display evidence of sub-clinical hypertrophic remodelling compared to age- and gender-matched controls [@bb0370; @bb0295]. The baseline results of this study support these findings with decreased blood pool volumes, increased LVMI and M/V ratio, and subtle abnormalities of systolic myocardial strains in patients compared to controls. The direction and magnitude of exercise-induced changes in LVM, LVMI and M/V ratio in both patient and control groups are consistent with normal physiological responses to aerobic exercise in untrained healthy controls [@bb0110; @bb0115; @bb0120]. Importantly, there was no significant effect of group status on the proportional degree of hypertrophic remodelling observed: patients and controls had similar responses to exercise. We found no significant effect of a 16-week endurance exercise training programme on left ventricular volumes or cardiac systolic or diastolic function, but acknowledge that these additional physiological changes may not have been appreciated in this time frame.

Consistent with previous studies, we found abnormal cardiac bioenergetics at baseline in patients harbouring the m.3243A\>G mutation [@bb0370]. In mitochondrial disease and other forms of inherited hypertrophic cardiomyopathy, several groups have suggested the primacy of bioenergetic defects by detection of abnormalities in mutation carriers without evidence of LVH [@bb0080; @bb0300; @bb0305]. Given that we also detected significant differences in cardiac remodelling, known to cause a reduction in PCr/ATP ratio, we cannot comment on the temporal relationship of these findings, but a reduced ratio has already been demonstrated to have prognostic importance in a variety of forms of cardiomyopathy [@bb0375]. Importantly therefore, we were able to demonstrate, using ^31^P cardiac MRS, that endurance exercise training had no further deleterious effect on the abnormal myocardial bioenergetics in our patients, despite the expected and modest physiological increase in LVMI. Indeed, following aerobic exercise training, *fewer* patients had an abnormal PCr/ATP ratio and the decreased mean ratio of the patient group was less evident compared to controls. Taken together, these morphological, functional and bioenergetic results suggest that a 16-week endurance exercise training programme has no deleterious effects on the heart in patients with mitochondrial disease due to the m.3243A\>G mutation. Given previous demonstrations of the beneficial effects of endurance exercise on exercise tolerance, quality of life and skeletal muscle function in this cohort of patients, this important result should allay fears of any detrimental cardiac response to endurance exercise and potentially enable more widespread adoption of a proven treatment in a population with currently limited therapeutic options.

4.3. Skeletal muscle oxidative capacity and sympathetic activation {#s0165}
------------------------------------------------------------------

Significant differences between patients and controls in resting heart rate and mean RR interval together with directionally opposing changes in low and high frequency components of both HRV and diastolic BPV provide evidence of a shift in the sympatho-vagal balance in patients harbouring the m.3243A\>G mutation. This finding is supported by an increased LF:HF ratio for both RR interval and diastolic blood pressure, suggesting increased sympathetic activity and a parallel reduction in parasympathetic function in patients. This is consistent with previous observations of resting sympathetic over-activity both in small studies of patients with mitochondrial disease and in larger cohorts of patients with other chronic diseases characterized by similar skeletal muscle dysfunction and exercise intolerance [@bb0310]. Our findings further corroborate reports of a hyperadrenergic state in patients with mitochondrial disease indicated by increased plasma concentration of noradrenaline in patients [@bb0215], and the high prevalence of sympathetic symptoms in this population [@bb0315]. Chronic sympathetic activation is recognised as detrimental contributing to vasoconstriction, tissue hypoxia, inflammation, oxidative stress, and impairment of muscle proton homeostasis; all factors that may lead to increased skeletal myopathy, hypertension and elevated cardiovascular risk [@bb0165; @bb0310; @bb0320]. The mechanisms underlying the effects of chronic sympathetic activation are largely unknown, but sympathetic outflow to skeletal muscle, which is dependent on both baroreceptor and chemoreceptor regulation, is heightened selectively in patients with other chronic diseases in which skeletal myopathy is recognised such as heart failure, COPD, essential hypertension and end stage renal disease [@bb0325; @bb0330; @bb0335; @bb0340]. It has been postulated that overactivity of skeletal muscle somatic afferents maintains an increased sympathetic drive both during exercise and at rest, contributing to skeletal myopathy [@bb0385]. These nerve fibres, which mediate the exercise pressor reflex, include metaboreceptors that are sensitive to ischaemic metabolites during exercise, including lactic acid, and mechanoreceptors that are primarily sensitive to stretch. Yet it has been shown that exercise intolerance and sympathetic activation are independent of lactic acidosis in patients with mitochondrial disease [@bb0350; @bb0355]. We propose that the increased sympathetic tone evident at baseline in patients, and the exaggerated neurovascular responses to exercise, with increased heart rate at equivalent cardiopulmonary work capacities and time intervals, may be at least partly due to increased skeletal muscle afferent mechanoreceptor sensitivity as seen in other chronic diseases with sympathetic overactivity and exercise intolerance [@bb0360]. Indeed our data also suggest a physiological upregulation of parasympathetic activity in patients in response to exercise training, similar in magnitude to the effect in control subjects. Further evaluation of the role of autonomic dysregulation and impact on disease burden, phenotypic expression and exercise intolerance in patients with mitochondrial disease is warranted. Such studies may help to discern the major limitations of exercise capacity in other chronic diseases associated with skeletal myopathy, in which mitochondrial dysfunction has been implicated, directing future therapeutic interventions.

4.4. Limitations {#s0170}
----------------

Although this study is the largest investigation of cardiac adaptations to exercise performed to date in this patient group, it remains limited in sample size, and duration, and was not designed to investigate pathogenetic mechanisms or disease progression. In an already extensive protocol, we did not make direct assessments of skeletal muscle function or bioenergetics. We studied a relatively homogenous cohort of patients, harbouring the single commonest mtDNA point mutation, without known cardiac involvement: such patients account for \~ 25% of our specialist clinic attendees yet we recognize that our findings may not be generalizable to all patients with mtDNA point mutations.

5. Conclusions {#s0025}
==============

Our data represent the first comprehensive evaluation of the cardiac safety and efficacy profile of aerobic, endurance exercise training in patients with m.3243A\>G-related mitochondrial disease. We have determined that endurance exercise training is safe in patients harbouring the m.3243A\>G mutation, and produces improvements in clinical parameters of a similar magnitude and direction to those observed in untrained, sedentary controls, and holds potential therapeutic benefits for patients with mitochondrial disease. We also provide evidence of altered sympatho-vagal balance with sympathetic over-activation in patients harbouring the m.3243A\>G mutation. This represents a further potential therapeutic target for pharmacological intervention or improved vagal tone with exercise. Identification of an effective intervention that could slow or reverse progression of skeletal muscle involvement in mitochondrial disease has the potential to achieve significant health gains with a substantial impact on patient health and well-being. Our findings underpin the future translation of effective exercise therapy into the clinical care of patients with mitochondrial disease.
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1-D1-dimensional^31^Pphosphorus-312,3-DPG2,3-disphosphoglycerateAMARESaccumulation method for accurate, robust and efficient spectraATPadenosine triphosphateCSIchemical shift imagingDNAdeoxyribonucleic acidDPGdiphosphoglycerateE/Aearly/late filling velocityECGelectrocardiographFAflip angleFOVfield of viewHCMhypertrophic cardiomyopathyLVleft ventricularLVHleft ventricular hypertrophyLVMIleft ventricular mass indexMELASmitochondrial encephalopathy with lactic acidosis and stroke-like episodeMIDDmaternally inherited diabetes and deafnessMRImagnetic resonance imagingMRSmagnetic resonance spectroscopymt-tRNAmitochondrial transfer RNAmtDNAmitochondrial DNAM/Vleft ventricular mass/end-diastolic volumeNMDASNewcastle Mitochondrial Disease Adult ScalePCrphosphocreatinePDEphosphodiestersppmparts per millionRNAribonucleic acidSDstandard deviationSENSEsensitivity encodingTEecho timeTRrepetition timeTSRtorsion to endocardial circumferential strain ratio
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![Cardiac tagging analysis. (A) Cine imaging (top panels) and tagging (bottom) at end-diastole (left panels) and end-systole (right). A rectangular grid of nulled myocardium applied in diastole enables tracking of myocardial deformation, including circumferential strain. (B) Tagging of 2 parallel short-axis slices allows calculation of torsion, the longitudinal--circumferential sheer angle (θ) as shown. Torsion describes the twisting motion of the heart due to opposite rotation of base and apex, and maintains homogeneity of strain across the myocardial wall. Increased torsion results from dominant contractile function in the subepicardium, compared to the subendocardium such that the torsion to endocardial circumferential strain ratio (TSR) is a sensitive marker of altered epicardial--endocardial interaction.](gr1){#f0005}

![Box-plot of range and quartiles of the increase in LV mass between baseline and 16-week follow-up assessment, after endurance exercise training, expressed as a percentage of the baseline assessment in patient and control groups. LV = left ventricular.](gr2){#f0010}

![Spaghetti plot of the change in (A) LVMI and (B) PCr/ATP ratio in patients (red, open squares) and controls (black, closed circles) following 16 weeks of endurance exercise training. Solid lines represent individual participants; dotted lines represent the corresponding mean group values; and vertical bars show the standard deviation at baseline (left) and following exercise training (right) in the respective groups. LVMI = left ventricular mass index; PCr = phosphocreatine; ATP = adenosine triphosphate; baseline = initial assessment; post-exercise = follow-up assessment after completion of 16 week exercise training.](gr3){#f0015}

![Phosphorus-31 magnetic resonance spectroscopy. Representative spectra from a patient carrying the m.3243A\>G mutation (left) and a matched control subject (right) at baseline (upper panels) and following completion of 16 week exercise training (lower panels) showing a difference in PCr concentration that is unaffected by exercise. Spectra obtained from patient 3 (A) at baseline with PCr/ATP ratio 1.1, and (B) following exercise training with PCr/ATP 1.2 are displayed alongside spectra from the matched control participant (C) at baseline with PCr/ATP 2.0, and (D) following exercise training with PCr/ATP 1.9. Spectra are presented as acquired before correction for heart rate, flip angle and blood content. PCr = phosphocreatine; ATP = adenosine triphosphate; ppm = parts per million.](gr4){#f0020}

###### 

Baseline characteristics.

  --------------------------------------------------------------------------
  Characteristic                     Patients\     Controls\     *p* value
                                     (n = 10)      (n = 10)      
  ---------------------------------- ------------- ------------- -----------
  Age (years)                        42.4 ± 10.5   39.0 ± 11.8   0.391

  Male sex, n (%)                    6 (60)        6 (60)        1.000

  Height (cm)                        171 ± 10      172 ± 10      0.707

  Weight (kg)                        62.1 ± 12.2   81.9 ± 12.9   0.002

  Body mass index (kg/m^2^)          21.3 ± 3.4    27.7 ± 4.7    0.002

  Body surface area (m^2^)           1.72 ± 0.19   1.95 ± 0.16   0.010

  Habitual physical activity                                     

   Daily energy expenditure (kCal)   2133 ± 666    2529 ± 373    0.118

   Daily steps (n)                   7949 ± 3968   9290 ± 2708   0.207

  Diabetes mellitus, n (%)           5 (50)        0 (0)         N/A

  Hypertension, n (%)                1 (10)        0 (0)         N/A

  Cardiac clinical parameters                                    

   Heart rate (min^− 1^)             75 ± 11       64 ± 10       0.033

   SBP (mm Hg)                       118 ± 11      114 ± 8       0.430

   DBP (mm Hg)                       81 ± 8        77 ± 7        0.181

  Selected medications                                           

   ACE inhibitor/ARB                 4 (40)        0 (0)         N/A

   Beta-blocker                      0 (0)         0 (0)         N/A

   Calcium channel blocker           1 (10)        0 (0)         N/A

   Insulin                           3 (30)        0 (0)         N/A

   Metformin                         2 (20)        0 (0)         N/A

   Statin                            4 (40)        0 (0)         N/A

   Co-enzyme Q10                     4 (40)        0 (0)         N/A

   Antidepressant                    2 (20)        0 (0)         N/A
  --------------------------------------------------------------------------

N/A = not applicable; SBP = systolic blood pressure; DBP = diastolic blood pressure; ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker.

###### 

Disease features of patients.

  Patient                              Age   Sex   Urinary m.3243A\>G mutation load (%)   Clinical features                                                                                                                                                              Baseline clinical scores              
  ------------------------------------ ----- ----- -------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------- ----- ---- ----
  1[a](#tf0035){ref-type="table-fn"}   39    M     80                                     SNHL, diabetes mellitus, exercise intolerance, ataxia, migraine, GIT, fatigue, hypothyroidism                                                                                  17                         44    38   37
  2                                    58    F     59                                     SNHL, exercise intolerance, mild ataxia, proximal muscle weakness, GIT, low BMI, myalgia                                                                                       12                         2     56   58
  3[a](#tf0035){ref-type="table-fn"}   42    M     82                                     SNHL, diabetes mellitus, exercise intolerance, ataxia, migraine, depression                                                                                                    12                         9     50   59
  4                                    47    M     63                                     SNHL, diabetes mellitus, exercise intolerance, ataxia, proximal and distal muscle weakness, depression, fatigue, myalgia, PEO, ptosis, sensory neuropathy                      28                         109   23   29
  5                                    37    F     48                                     SNHL, diabetes mellitus, exercise intolerance, mild ataxia, mild dysarthria, asthma                                                                                            10                         13    52   53
  6                                    38    F     53                                     SNHL, exercise intolerance, proximal muscle weakness, fatigue, migraine, GIT, asthma                                                                                           13                         29    32   55
  7                                    22    M     89                                     SNHL, exercise intolerance, ataxia, fatigue, migraine, GIT, low BMI, epilepsy                                                                                                  18                         62    40   46
  8                                    36    M     80                                     Exercise intolerance, migraine                                                                                                                                                 4                          9     57   54
  9                                    50    M     87                                     SNHL, exercise intolerance, ataxia, proximal and distal muscle weakness, fatigue, depression, retinopathy, epilepsy, encephalopathy, cognitive decline, stroke-like episodes   23                         68    57   46
  10                                   55    F     68                                     SNHL, diabetes mellitus, exercise intolerance, ataxia, proximal muscle weakness, GIT, depression, retinopathy, PEO, ptosis, short stature, mild dysphagia, hypertension        25                         23    36   49

NMDAS = Newcastle Mitochondrial Disease Adult Scale; M = male; F = female; MIDD = maternally inherited deafness and diabetes; MELAS = mitochondrial encephalopathy, lactic acidosis and stroke-like episodes; FIS = Fatigue Impact Scale; SF-12 = Short Form-12 quality of life questionnaire; PHC = physical health component; MHC = mental health component .

Sibling.

###### 

Exercise parameters before and after training.

  Parameter                          Patients     Controls     Interaction *p* value[b](#tf0010){ref-type="table-fn"}                                                                                                        
  ---------------------------------- ------------ ------------ -------------------------------------------------------- ---------------------------------------------- --------------------------------------------- ------- -------
  *Peak exercise*                                                                                                                                                                                                            
  Heart rate                         167 ± 21     161 ± 18     0.299                                                    184 ± 17                                       178 ± 14[⁎](#tf0015){ref-type="table-fn"}     0.001   0.921
  SBP (mm Hg)                        183 ± 24     193 ± 21     0.082                                                    188 ± 18                                       194 ± 16                                      0.183   0.744
  DBP (mm Hg)                        94 ± 17      93 ± 15      0.880                                                    99 ± 12                                        89 ± 17                                       0.069   0.222
  MAP (mm Hg)                        124 ± 15     126 ± 13     0.535                                                    129 ± 10                                       124 ± 13                                      0.260   0.258
  Stroke volume (ml)                 91 ± 23      95 ± 29      0.532                                                    116 ± 20[⁎⁎](#tf0040){ref-type="table-fn"}     118 ± 26                                      0.774   0.786
  Stroke index (ml/m^2^)             53 ± 9       54 ± 12      0.687                                                    59 ± 9                                         60 ± 9                                        0.832   0.695
  Cardiac output (l/min)             14.5 ± 3.9   15.1 ± 4.8   0.398                                                    21.3 ± 4.1[⁎⁎](#tf0040){ref-type="table-fn"}   21.0 ± 4.8[⁎](#tf0015){ref-type="table-fn"}   0.946   0.643
  Cardiac index (l/min/m^2^)         8.3 ± 1.5    8.6 ± 2.1    0.681                                                    10.6 ± 1.2[⁎⁎](#tf0040){ref-type="table-fn"}   10.4 ± 1.5                                    0.828   0.517
  VO~2~ (ml/min)                     1382 ± 625   1596 ± 726   0.030                                                    2276 ± 670[⁎⁎](#tf0040){ref-type="table-fn"}   2525 ± 562[⁎](#tf0015){ref-type="table-fn"}   0.049   0.983
  VO~2~ (ml/kg/min)                  21.4 ± 6.3   24.8 ± 8.9   0.009                                                    27.6 ± 6.3[⁎](#tf0015){ref-type="table-fn"}    30.4 ± 5.9                                    0.047   0.965
  VO~2~ (% predicted VO~2~)          61 ± 20      72 ± 25      0.011                                                    94 ± 21[⁎⁎](#tf0040){ref-type="table-fn"}      106 ± 26[⁎⁎](#tf0040){ref-type="table-fn"}    0.032   0.882
  CPO                                4.0 ± 1.3    4.0 ± 1.2    0.708                                                    5.7 ± 1.0[⁎⁎](#tf0040){ref-type="table-fn"}    5.4 ± 1.2[⁎](#tf0015){ref-type="table-fn"}    0.408   0.413
  CPOI                               2.3 ± 0.5    2.3 ± 0.5    0.732                                                    2.7 ± 0.4                                      2.8 ± 0.5                                     0.396   0.294
  Power (W)                          100 ± 45     112 ± 55     0.044                                                    177 ± 40[⁎⁎](#tf0040){ref-type="table-fn"}     200 ± 39[⁎⁎](#tf0040){ref-type="table-fn"}    0.001   0.621
  A--VO~2~ diff (ml O~2~/dl)         9.4 ± 3.0    10.5 ± 3.1   0.059                                                    10.9 ± 2.9[⁎](#tf0015){ref-type="table-fn"}    11.8 ± 1.9[⁎](#tf0015){ref-type="table-fn"}   0.242   0.736
                                                                                                                                                                                                                             
  *Anaerobic threshold*                                                                                                                                                                                                      
  ATVO~2~ (ml/kg/min)                13.4 ± 5.0   16.5 ± 6.4   0.014                                                    15.4 ± 4.1                                     18.8 ± 4.1                                    0.017   0.772
  ATVO~2~ (% predicted peak VO~2~)   38 ± 14      47 ± 18      0.221                                                    53 ± 14[⁎](#tf0015){ref-type="table-fn"}       65 ± 19[⁎⁎](#tf0040){ref-type="table-fn"}     0.032   0.665
  ATVO~2~ (% recorded peak VO~2~)    61 ± 8       66 ± 5       0.128                                                    56 ± 7                                         63 ± 5                                        0.049   0.758

SBP = systolic blood pressure; DBP = diastolic blood pressure; MAP = mean arterial pressure; VO~2~ = oxygen uptake; AT = anaerobic threshold; CPO = cardiac power output; CPOI = cardiac power output index; A--VO~2~ diff = arterial--venous oxygen difference; AT = anaerobic threshold.

*p* value represents the within group comparison of paired before and follow-up time points.

*p* value represents group by time interaction from mixed model repeated measures analysis.

*p* \< 0.05 for patients vs. controls at equivalent time points.

*p* \< 0.01 for patients vs. controls at equivalent time points.

###### 

Cardiac parameters before and after exercise training.

  Parameter                                Patients      Controls      Interaction *p* value[b](#tf0025){ref-type="table-fn"}                                                                                                           
  ---------------------------------------- ------------- ------------- -------------------------------------------------------- ----------------------------------------------- ----------------------------------------------- ------- -------
  *Structure and systolic function*                                                                                                                                                                                                     
  EDV (ml)                                 96 ± 21       101 ± 17      0.120                                                    136 ± 25[⁎⁎](#tf0045){ref-type="table-fn"}      139 ± 20[⁎⁎](#tf0045){ref-type="table-fn"}      0.305   0.737
  EDI (ml/m^2^)                            55 ± 8        58 ± 6        0.138                                                    69 ± 10[⁎⁎](#tf0045){ref-type="table-fn"}       71 ± 8[⁎⁎](#tf0045){ref-type="table-fn"}        0.224   0.992
  ESV (ml)                                 38 ± 13       41 ± 13       0.158                                                    56 ± 13[⁎⁎](#tf0045){ref-type="table-fn"}       56 ± 14[⁎](#tf0030){ref-type="table-fn"}        0.972   0.551
  ESI (ml/m^2^)                            22 ± 6        23 ± 6        0.184                                                    29 ± 5[⁎](#tf0030){ref-type="table-fn"}         29 ± 6                                          0.898   0.646
  SV (ml)                                  58 ± 9        60 ± 6        0.342                                                    79 ± 14[⁎⁎](#tf0045){ref-type="table-fn"}       83 ± 10[⁎⁎](#tf0045){ref-type="table-fn"}       0.354   0.926
  SI (ml/m^2^)                             33 ± 3        35 ± 3        0.340                                                    41 ± 6[⁎⁎](#tf0045){ref-type="table-fn"}        43 ± 5[⁎⁎](#tf0045){ref-type="table-fn"}        0.281   0.537
  CO (l/min)                               4.3 ± 0.7     4.2 ± 0.7     0.502                                                    5.0 ± 1.0                                       5.1 ± 1.0                                       0.755   0.843
  CI (l/min/m^2^)                          2.5 ± 0.2     2.4 ± 0.4     0.419                                                    2.6 ± 0.4                                       2.7 ± 0.5                                       0.689   0.528
  EF (%)                                   61 ± 5        60 ± 7        0.515                                                    59 ± 4                                          60 ± 6                                          0.489   0.410
  LS (%)                                   14.8 ± 0.2    13.2 ± 0.3    0.213                                                    18.1 ± 0.2[⁎⁎](#tf0045){ref-type="table-fn"}    17.3 ± 0.3[⁎](#tf0030){ref-type="table-fn"}     0.553   0.573
  LVM (g)                                  124 ± 20      140 ± 21      0.003                                                    116 ± 20                                        134 ± 26                                        0.001   0.989
  LVMI (g/m^2^)                            72 ± 13       81 ± 10       0.004                                                    59 ± 8[⁎](#tf0030){ref-type="table-fn"}         69 ± 11[⁎](#tf0030){ref-type="table-fn"}        0.002   0.666
  M/V ratio (g/ml)                         1.35 ± 0.40   1.41 ± 0.26   0.302                                                    0.86 ± 0.07[⁎⁎](#tf0045){ref-type="table-fn"}   0.97 ± 0.11[⁎⁎](#tf0045){ref-type="table-fn"}   0.003   0.620
                                                                                                                                                                                                                                        
  *Diastolic function*                                                                                                                                                                                                                  
  E/A ratio                                1.65 ± 0.62   1.45 ± 0.57   0.387                                                    1.65 ± 0.40                                     1.83 ± 0.43                                     0.320   0.451
  EFP (%)                                  67.7 ± 6.7    70.7 ± 14.1   0.468                                                    72.7 ± 7.6                                      73.9 ± 6.4                                      0.698   0.557
                                                                                                                                                                                                                                        
  *Tagging and strains*                                                                                                                                                                                                                 
  Torsion (°)                              9.1 ± 3.5     7.9 ± 1.0     0.337                                                    5.9 ± 1.9[⁎](#tf0030){ref-type="table-fn"}      6.7 ± 1.5[⁎](#tf0030){ref-type="table-fn"}      0.057   0.292
  Whole wall circumferential strain (%)    16.4 ± 1.9    16.7 ± 1.4    0.624                                                    17.8 ± 1.8                                      18.6 ± 3.4                                      0.435   0.714
  Endocardial circumferential strain (%)   20.6 ± 2.0    20.0 ± 2.0    0.353                                                    24.7 ± 2.3[⁎⁎](#tf0045){ref-type="table-fn"}    25.9 ± 5.2[⁎](#tf0030){ref-type="table-fn"}     0.367   0.713
  TSR (rad)                                0.80 ± 0.38   0.71 ± 0.10   0.555                                                    0.41 ± 0.12[⁎⁎](#tf0045){ref-type="table-fn"}   0.46 ± 0.09[⁎⁎](#tf0045){ref-type="table-fn"}   0.325   0.292
                                                                                                                                                                                                                                        
  *Cardiac high energy phosphates*                                                                                                                                                                                                      
  PCr/ATP ratio                            1.45 ± 0.42   1.61 ± 0.39   0.260                                                    1.95 ± 0.34[⁎⁎](#tf0045){ref-type="table-fn"}   1.97 ± 0.37[⁎](#tf0030){ref-type="table-fn"}    0.907   0.749

EDV = end-diastolic volume; ESI = end-diastolic index; ESV = end-systolic volume; ESI = end-systolic index; SV = stroke volume; SI = stroke index; CO = cardiac output; CI = cardiac index; EF = ejection fraction; LS = longitudinal shortening; LVM = left ventricular mass; LVMI = left ventricular mass index; M/V ratio = ratio of left ventricular mass to volume; E/A ratio = ratio of early to late ventricular filling velocity; EFP = early filling percentage; TSR = torsion to (endocardial) strain ratio; PCr = phosphocreatine; ATP = adenosine triphosphate.

*p* value represents the within group comparison of paired before and follow-up time points.

*p* value represents group by time interaction from mixed model repeated measures analysis.

*p* \< 0.05 for patients vs. controls at equivalent time points.

*p* \< 0.01 for patients vs. controls at equivalent time points.

###### 

Autonomic parameters and fatigue before and after exercise training.

  Parameter                      Patients     Controls     Interaction *p* value^b^                                           
  ------------------------------ ------------ ------------ -------------------------- -------------- ---------------- ------- -------
  *Heart rate variability*                                                                                                    
  Mean RRI (ms)                  808 ± 101    854 ± 112    0.220                      891 ± 102^⁎^   948 ± 119^⁎^     0.128   0.568
  LFnu-RRI                       68 ± 18      64 ± 19      0.711                      54 ± 12^⁎⁎^    48 ± 17^⁎^       0.086   0.591
  HFnu-RRI                       46 ± 18      48 ± 19      0.711                      49 ± 22        58 ± 25          0.086   0.591
  PSD-RRI                        1472 ± 923   1976 ± 979   0.083                      1248 ± 824     2084 ± 1094      0.051   0.769
  LF:HF-RRI                      3.4 ± 0.9    2.8 ± 1.5    0.249                      1.9 ± 1.7^⁎^   1.9 ± 1.8        0.994   0.380
                                                                                                                              
  *Blood pressure variability*                                                                                                
  LFnu-SBP                       47 ± 9       44 ± 14      0.613                      42 ± 13        38 ± 19          0.274   0.843
  HFnu-SBP                       18 ± 10      20 ± 15      0.729                      26 ± 8         28 ± 11          0.950   0.852
  PSD-SBP                        9.0 ± 2.7    11.8 ± 7.1   0.169                      10.9 ± 6.3     12.5 ± 9.8       0.716   0.543
  LF:HF-SBP                      3.9 ± 1.8    3.7 ± 2.7    0.330                      3.0 ± 2.6      2.8 ± 3.5        0.830   0.503
  LFnu-DBP                       51 ± 14      47 ± 15      0.317                      48 ± 15        43 ± 17          0.382   0.969
  HFnu-DBP                       13 ± 9       18 ± 11      0.081                      20 ± 11^⁎^     29 ± 13^⁎⁎^      0.006   0.767
  PSD-DBP                        4.9 ± 2.0    6.0 ± 3.7    0.088                      7.1 ± 2.4^⁎^   10.6 ± 5.6^⁎⁎^   0.341   0.430
  LF:HF-DBP                      6.1 ± 2.5    5.6 ± 2.1    0.278                      4.2 ± 2.1^⁎^   3.9 ± 2.5        0.278   0.127
                                                                                                                              
  *Fatigue*                                                                                                                   
  FIS score                      37 ± 34      34 ± 37      0.350                      9 ± 11^⁎^      5 ± 8^⁎⁎^        0.087   0.928

FIS = Fatigue Impact Scale; LF = low frequency; HF = high frequency; SBP = systolic blood pressure; DBP = diastolic blood pressure; nu = normalized units; PSD = power spectral density; RRI = RR interval. ^a^ p value represents the within group comparison of paired before and follow-up time points. ^b^ p value represents group by time interaction from mixed model repeated measures analysis. \* p \< 0.05 for patients vs. controls at equivalent time points. \*\* p \< 0.01 for patients vs. controls at equivalent time points.

[^1]: These authors contributed equally to this work.
